Last reviewed · How we verify
NCT06975371
Real-World Outcomes of Patients With Metastatic Breast Cancer After Treatment With First-Line ET+CDK4/6i
trial testing No drug in Advanced/Metastatic HER2-negative Breast Cancer in 1,415 participants. Completed in 5 August 2025.
8 May 2025
Quick facts
| Lead sponsor | Daiichi Sankyo |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,415 |
| Start date | 14 April 2025 |
| Primary completion | 8 May 2025 |
| Estimated completion | 5 August 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- No drug — full drug profile →
Conditions studied
- Advanced/Metastatic HER2-negative Breast Cancer — all drugs for Advanced/Metastatic HER2-negative Breast Cancer →
Sponsor
Daiichi Sankyo — full company profile →
Who can join
18 and older, any sex, with Advanced/Metastatic HER2-negative Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to assess the treatment patterns and real-world outcomes of HR+/HER- metastatic breast cancer patients who have progressed on 1L ET + CDK4/6i and started a second line (2L) treatment within a real-world cohort in the United States Flatiron Health Database.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06975371
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of No drug
Trials testing the same drug.
- NCT07092254 — Patterns of Care and Outcomes in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer · active not recruiting
- NCT06809764 — Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN) · recruiting
- NCT06833268 — Real-world Outcomes of Patients With HER2+ Metastatic Breast Cancer After Treatment With Trastuzumab Deruxtecan · completed
- NCT06617390 — A Study of Real-world Treatment Patterns and Outcomes in Chinese Advanced NSCLC Patients Who Previously Received at Leas · completed
- NCT06585501 — A Study of Treatment Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in Ch · completed
Other Daiichi Sankyo trials
Trials by the same sponsor.
- NCT07474649 — A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events · Phase 3 · not yet recruiting
- NCT07206472 — A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Patients With Primary Hypercholestero · active not recruiting
- NCT07220616 — A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies · Phase 1, PHASE2 · recruiting
- NCT07268625 — Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid / Ezetimibe, and Atorv · Phase 1 · completed
- NCT07244341 — A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer ( · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06975371 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Daiichi Sankyo
- Last refreshed: 7 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06975371.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing